138 related articles for article (PubMed ID: 15095281)
1. Anaplastic lymphoma kinase proteins in growth control and cancer.
Pulford K; Morris SW; Turturro F
J Cell Physiol; 2004 Jun; 199(3):330-58. PubMed ID: 15095281
[TBL] [Abstract][Full Text] [Related]
2. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
3. The emerging normal and disease-related roles of anaplastic lymphoma kinase.
Pulford K; Lamant L; Espinos E; Jiang Q; Xue L; Turturro F; Delsol G; Morris SW
Cell Mol Life Sci; 2004 Dec; 61(23):2939-53. PubMed ID: 15583856
[TBL] [Abstract][Full Text] [Related]
4. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
5. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
6. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
7. Translocations involving anaplastic lymphoma kinase (ALK).
Duyster J; Bai RY; Morris SW
Oncogene; 2001 Sep; 20(40):5623-37. PubMed ID: 11607814
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
[TBL] [Abstract][Full Text] [Related]
9. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
10. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical screening for oncogenic tyrosine kinase activation.
Pulford K; Delsol G; Roncador G; Biddolph S; Jones M; Mason DY
J Pathol; 1999 Apr; 187(5):588-93. PubMed ID: 10398126
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
[TBL] [Abstract][Full Text] [Related]
14. Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene.
Yamamoto H; Kohashi K; Oda Y; Tamiya S; Takahashi Y; Kinoshita Y; Ishizawa S; Kubota M; Tsuneyoshi M
Pathol Int; 2006 Oct; 56(10):584-90. PubMed ID: 16984614
[TBL] [Abstract][Full Text] [Related]
15. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
16. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
Turner SD; Tooze R; Maclennan K; Alexander DR
Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic apoptotic pathway in anaplastic large cell lymphoma.
Oyarzo MP; Drakos E; Atwell C; Amin HM; Medeiros LJ; Rassidakis GZ
Hum Pathol; 2006 Jul; 37(7):874-82. PubMed ID: 16784988
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
Hsu FY; Zhao Y; Anderson WF; Johnston PB
Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
20. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
Chikatsu N; Kojima H; Suzukawa K; Shinagawa A; Nagasawa T; Ozawa H; Yamashita Y; Mori N
Mod Pathol; 2003 Aug; 16(8):828-32. PubMed ID: 12920229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
